Michael Searles

Michael Searles is a health and science journalist at The Telegraph. His work focuses on cancer research, medical advancements, and the NHS. He often reports on clinical trials and new treatments for various types of cancer. Searles also covers stories related to healthcare policies, hospital incidents, and medical professionals' actions.

Biography:  https://www.telegraph.co.uk/authors/m/mf-mj/michael-searles/

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

95%

Examples:

  • Michael Searles tends to report positively about advancements in cancer treatment and vaccines.
  • Several articles highlight the effectiveness of pembrolizumab, a drug with which Searles appears to have a connection.

Conflicts of Interest

100%

Examples:

  • Several articles highlight the effectiveness of pembrolizumab, a drug with which Searles appears to have a connection.

Contradictions

85%

Examples:

  • 100% clinical complete response rate in patients with dMMR locally advanced rectal cancer who completed treatment with dostarlimab-gxly.
  • 59% of patients whose tumours shrank significantly had no signs of disease when their affected bowel sections were removed.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

DIY Home Cervical Cancer Tests: A Game-Changer for Increased Coverage and Earlier Detection

DIY Home Cervical Cancer Tests: A Game-Changer for Increased Coverage and Earlier Detection

Broke On: Tuesday, 16 July 2024 New DIY home cervical cancer tests offer convenience and increased accessibility, potentially reaching 400,000 more women annually for screening. Self-sampling trial results show benefits for ethnic minorities and deprived populations. NHS assessing rollout in England to increase coverage from 69.9% to 77.3%. Tests detect HPV and offer choice, but should not replace professional medical advice.
Immunotherapy Drugs Jemperli and Pembrolizumab Show Promise in Improving Survival Rates for Certain Bowel Cancer Patients: ASCO 2024

Immunotherapy Drugs Jemperli and Pembrolizumab Show Promise in Improving Survival Rates for Certain Bowel Cancer Patients: ASCO 2024

Broke On: Monday, 03 June 2024 Immunotherapy drugs Jemperli and pembrolizumab show promising results in improving survival rates for certain bowel cancer patients, potentially replacing or reducing the need for surgery and chemotherapy, according to clinical trial findings presented at ASCO 2024.